http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PH-22018000345-U1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2385552ea1fcf7f43527c6a0694826f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-888 |
| filingDate | 2018-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4dd1a77a81b8ecf58c627ee41253acbb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_113b7f14a7161477c121a157cc619540 |
| publicationDate | 2021-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PH-22018000345-U1 |
| titleOfInvention | Natural products derived from amlong (rhapidophora merrilii) for treatment of diabetes |
| abstract | The present technology relates to plants showing significant glucosidase inhibitory activity, or preventing the conversion of carbohydrate to simple sugars by glucosidase enzymes, hence useful for treating diabetes. Specifically, the present technology provides a process for producing a natural product from Amlong(Rhapidophora merrillii) plant which is found to show significant inhibition for a-glucosidase. Leaves of Amlong were extracted using methanol, and derivatives from the Amlong methanol extract were obtained by partitioning into water, n-hexane, and ethyl acetate solvents. The derivatives of Amlong (Rhapidophora merrillii) obtained were tested and found to exhibit significant but varying degrees of glucosidase inhibitory activity as compared to a standard glucosidase inhibitor acarbose. The present technology also provides a natural medicament using the derivatives obtained from Amlong for treatment of diabetes. |
| priorityDate | 2018-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.